Biomarin Pharmaceutical (BMRN) Net Cash Flow (2009 - 2026)

Biomarin Pharmaceutical has disclosed Net Cash Flow across 18 years of filings, most recently posting $1.8 billion for Q1 2026.

• Quarterly Net Cash Flow rose 1538.48% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 573.72% YoY) and the FY2025 annual result came in at $371.4 million, up 103.06% from the prior year.
• Net Cash Flow improved to $1.8 billion in Q1 2026, from $60.4 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $1.8 billion in Q1 2026 and troughed at -$293.8 million in Q3 2024.
• A 5-year average of $145.9 million and a median of $60.4 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 947.55% — and 2026, when it surged 1538.48%.
• Tracing BMRN's Net Cash Flow over 5 years: stood at -$37.1 million in 2022, then grew by 28.11% to -$26.6 million in 2023, then surged by 1094.33% to $264.9 million in 2024, then plunged by 77.22% to $60.4 million in 2025, then jumped by 2815.14% to $1.8 billion in 2026.
• Business Quant data shows BMRN's Net Cash Flow at $1.8 billion in Q1 2026, $60.4 million in Q4 2025, and $35.6 million in Q3 2025.